Skip to main content
Premium Trial:

Request an Annual Quote

Tataa Biocenter, SimplicityBio Plan to Offer Biomarker Discovery Products

NEW YORK (GenomeWeb) – Sweden's Tataa Biocenter announced today that it has partnered with in silico solutions provider SimplicityBio to market products for biomarker discovery, signature optimization, and validation on a variety of platforms.

The partners will combine their products to offer a complete solution for biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation, with the goal of developing diagnostics, prognostics, and theranostics based on reliable biomarker signatures. Platforms include microarrays, qPCR, dPCR, and next-generation sequencing, and almost any kind of biomarker with an emphasis on mRNA, microRNA, lncRNA, SNPs, CNVs, methylation markers, cfDNA, proteins, and circulating tumor cells.

Further terms of the deal were not disclosed.

Matthew Hall, CSO of Monthey, Switzerland-based SimplicityBio, said in a statement that Tataa's ability to generate genomic data based on its analysis pipelines is ideal for SimplicityBio's biomarker discovery and modeling pipelines.